INSIGHTS ON CONTRACT PHARMA MANUFACTURING

• From The Floor At CPHI 2025: Takeaways Everyone Should Know

  Gain insights into evolving pharma priorities, from supply chain resilience to advanced manufacturing, and why flexibility, scalability, and technical expertise matter in a dynamic global market.

• CDMO Capabilities Overview

  Explore global CDMO capabilities that streamline drug development and manufacturing, leveraging advanced infrastructure and regulatory expertise from early formulation through commercial production.

• Zhunan Facility Site VR Tour

  Bora’s 36,000-square-meter Zhunan, Taiwan facility delivers flexible, high-quality cGMP oral solid dose manufacturing with access to major markets including North America and the EU.

• Corporate Overview 2025: Business Strategy & Outlook

  Explore how a growing pharma organization uses innovation, regulatory expertise, and strategic partnerships to deliver targeted therapies and drive impact across the evolving healthcare landscape.

• State-Of-The-Art CDMO Facility - Maple Grove

  Discover how a U.S.-based CDMO combines advanced infrastructure, quality-driven processes, and flexible manufacturing to support pharmaceutical development and commercial supply.

• The Impact Of PEGs In The Small Molecule API Market

  Explore how PEG selection shapes drug development success by understanding the benefits of expert CDMO partnerships that deliver custom solutions to enhance your small molecule program.

• The Evolution Of Biotech And CDMO Partnerships: A 2026 Outlook

  By integrating R&D and GMP teams early, developers can navigate complex formulation challenges and ensure a seamless transition from first-in-human trials to late-stage clinical manufacturing.

• Periodic Counter Current Chromatography: A Step Toward Continuous DSP

  PCC boosts Protein A capture efficiency, cuts resin costs, increases productivity, and enables continuous downstream processing without sacrificing quality or compliance.

   

• Agile Adaptation In mRNA-LNP Manufacturing: A CDMO's Response

  Find flexible scale-up from lab through commercial manufacturing, leveraging expertise. Gain technical insights for scalable, efficient development for advancing mRNA, saRNA, or circular RNA programs.

• De-Risking FIH: Integrated Strategies For Rapid Proof-Of-Concept

  Proper planning for first-in-human studies is crucial to successful drug development, which requires innovative trial designs and sound CMC strategies to mitigate risk and expedite proof-of-concept.